| Record ID | marc_columbia/Columbia-extract-20221130-009.mrc:45836731:3732 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-009.mrc:45836731:3732?format=raw |
LEADER: 03732mam a2200385 a 4500
001 4045344
005 20221027023829.0
008 950104t19951995flua b 101 0 eng d
020 $a0849347645
035 $a(OCoLC)31765319
035 $a(OCoLC)ocm31765319
035 $9AKF5250HS
035 $a(NNC)4045344
035 $a4045344
040 $aJHW$cJHW$dNNC-M$dOrLoB
245 00 $aCamptothecins :$bnew anticancer agents /$cedited by Milan Potmesil and Herbert Pinedo.
260 $aBoca Raton, FL :$bCRC Press,$c[1995], ©1995.
300 $a149 pages :$billustrations ;$c23 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
500 $aBased on the Fourth Conference on DNA Topoisomerases in Therapy held in New York City in October 1992.
504 $aIncludes bibliographical references and index.
505 0 $aIntroduction / Milan Potmesil and Herbert Pinedo -- Ch. 1. Biochemistry of Camptothecin / Leroy F. Liu -- Ch. 2. Camptothecin and Analogs: From Discovery to Clinic / Monroe E. Wall and Mansukh C. Wani -- Ch. 3. Twenty Years Later: Review of Clinical Trials with Camptothecin Sodium (NSC-100880) / Franco Muggia -- Ch. 4. Preclinical Development of 20 (S)-Camptothecin, 9-Aminocamptothecin and Other Analogs / Milan Potmesil and Beppino C. Giovanella -- Ch. 5. Phase I Clinical Trial and Pharmacokinetic Results with Oral Administration of 20(S)-Camptothecin / John S. Stehlin, Ethan A. Natelson, Hellmuth R. Hinz, Beppino C. Giovanella, Peter D. de Ipolyi, Kim M. Fehir, Thomas P. Trezona, Dana M. Vardeman, Nicholas J. Harris, Alice K. Marcee, Anthony J. Kozielski and Amado Ruiz-Razura -- Ch. 6. Clinical Studies of CPT-11 in Japan / Tetsuo Taguchi.
505 8 $aCh. 7. Clinical Trials and Pharmacokinetic Studies of CPT-11 in the United States / Mace L. Rothenberg, Eric K. Rowinsky, John G. Kuhn, Howard A. Burris III, Ross C. Donehower and Daniel D. Von Hoff -- Ch. 8. Clinical Trials and Pharmacology Studies of CPT-11 and its Active Metabolite SN-38 in France: Preliminary Pharmacokinetic-Pharmacodynamic Relationships / Guy G. Chabot, Marcel de Forni, Daniel Abigerges, Jean-Pierre Armand, Michel Clavel, Roland Bugat, Stephane Culine, Jean-Marc Extra, Michel Marty, Marie-Christine Bissery, Anne Mathieu-Boue, Patrice Herait and Alain Gouyette -- Ch. 9. Topotecan Clinical Trials in the United States / Howard Hochster -- Ch. 10. Clinical Trials of Topotecan in Europe / Jaap Verweij, Wim ten Bokkel Huinink, Birthe Lund, Andre Planting, Jos Beijnen, Maureen de Boer-Dennert, Hilde Rosing, Ineke Koier and Heine Hansen -- Ch. 11. Camptothecins: Dose-Limiting Toxicities and Their Management / Howard A. Burris III, Suzanne M. Fields, John G. Kuhn and Daniel D. Van Hoff.
505 8 $aCh. 12. Cellular Determinants of Sensitivity and Resistance to Camptothecins / Yves Pommier, Akihiko Tanizawa, Kosuke Okada and Toshiwo Andoh -- Ch. 13. The Perspectives / Milan Potmesil and Herbert Pinedo.
650 2 $aCamptothecin$xpharmacokinetics.$0https://id.nlm.nih.gov/mesh/D002166Q000493
650 2 $aCamptothecin$xpharmacology.$0https://id.nlm.nih.gov/mesh/D002166Q000494
650 2 $aCamptothecin$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D002166Q000627
650 2 $aClinical Trials as Topic.$0https://id.nlm.nih.gov/mesh/D002986
650 2 $aNeoplasms$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D009369Q000188
655 2 $aCongress.$0https://id.nlm.nih.gov/mesh/D016423
700 1 $aPotmesil, Milan.$0http://id.loc.gov/authorities/names/n88077339
700 1 $aPinedo, H. M.$0http://id.loc.gov/authorities/names/n78080586
711 2 $aConference on DNA Topoisomerases in Therapy$n(4th :$d1992 :$cNew York, N.Y.)
852 00 $boff,hsl$hRC271.C35$iC35 1995